- LOGIN
- MemberShip
- 2020-10-24 11:41
Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Membership login access would be required from February 2020 to access more news and website services.
- Company
- Sanofi, to supply flu vaccine, Vaxigriptetra nationwide
- by Sep 17, 2020 06:29am
- Sanofi Pasteur (CEO Pascal Robin) announced on the 15th that it has supplied the flu vaccine 'Vaxigriptetra' nationwide. Sanofi Pasteur said that this year's flu vaccine is included in the NIP, and as the number of recipients expanded due to the spread of COVID-19, patients in need of flu prevention can receive the vaccine on time. Vaxigr
- Company
- Growth hormone market fluctuates with Pfizer’s supply issue
- by Kim, Jin-Gu Sep 17, 2020 06:29am
- The growth hormone injection market generating annual sales of 150 billion won had a fluctuating sales rank in the first half of the year. While LG Chem is still leading the market, Pfizer in the second place was dropped to the fifth place due to its global supply suspension. On the contrary, LG Chem, Dong-A ST and Novo Nordisk boosted their
- Company
- Where can clinics get flu vaccines?
- by Sep 16, 2020 06:26am
- "All pharmaceutical companies say they don't have flu vaccine stock. I am already worried because the quantity I received from the public health center is small." A Doctor of Clinic A in Seoul said in this way that he called all of the sales staff at pharmaceutical companies that supply flu vaccines, but said it was hard to get supplies.
- Company
- Talks on new payment system in the age of high-cost drugs
- by Eo, Yun-Ho Sep 16, 2020 06:25am
- Pharmaceutical experts are initiating talks on setting adequate Incremental Cost-Effectiveness Ratio (ICER) threshold to design a new payment model fitting the age of high-cost drug. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific 2020, convened online from Sept. 14 through 16, would be hosting
- Company
- Boryung,launches Tuvero (Arahkor Pre) in Mexico
- by An, Kyung-Jin Sep 16, 2020 06:25am
- Boryung announced on the 14th that it held a web symposium of Tuvero, a combination drug for hypertension and dyslipidemia, based on Kanarb in Mexico on the 11th (time in Korea) and began to launch in earnest. Tuvero is a combination drug that includes Kanarb(Fimasartan), an ARB (angiotensin II receptor blocker)-based hypertension drug
- Company
- ST Pharm, registered a global phase I of STP1002
- by An, Kyung-Jin Sep 16, 2020 06:25am
- A US clinical trial of a new oral colon cancer treatment drug being developed by ST Pharm is on track. One out of three local clinical trial institutions that announced their entry this year began recruiting subjects, taking the first step toward commercialization. According to clinicaltrials.gov operated by the National Institutes of Heal
- Company
- Giotrif competitor Vizimpro close to receiving reimbursement
- by Eo, Yun-Ho Sep 15, 2020 06:27am
- Sources report, Pfizer Korea is speeding up the procedure to introduce epidermal growth factor receptor (EGRF) tyrosine kinase inhibitors (TKI) into the market. According to the industry sources, a fifth EPGF TKI Vizimpro (dacomitini) has passed the Health Insurance Assessment and Review Service (HIRA) Cancer Deliberation Committee in la
- Company
- The sales of antiemetic drug Nasea plummeted
- by Kim, Jin-Gu Sep 15, 2020 06:26am
- Sales in the domestic market declined after three types of domestic copyright rights, including the antiemetic drug Nasea (Ramosetron), were transferred from Astellas to Daiichi Sankyo, a Japanese pharmaceutical company. According to IQVIA, a drug research institute, Nasea's sales in the first half of this year were &8361;12.7 billion, d
- Company
- Listed pharma companies financially sound despite COVID-19
- by Kim, Jin-Gu Sep 14, 2020 06:16am
- Apparently, major South Korean pharmaceutical and bio companies have been maintaining the level of financial soundness from late last year for the first half of this year. One of their financial soundness indicators, net liabilities, showed similar level as late last year, which the experts analyze the industry is performing relatively well,
- Company
- Expectations on Zejula are high
- by Sep 14, 2020 06:15am
- “The biggest burden on recurrent ovarian cancer patients is definitely 'relapse'. Zejula can play an important role for patients by preventing recurrence through primary maintenance therapy. In particular, it can be used as an All-comer. The appearance of Zejula is likely to make a big difference in the treatment of ovarian cancer.” Soo
